RETRANSMISSION: Akanda Researching Security Requirements for Full Cultivation LicenseNovember 14, 2025 8:30 AM EST | Source: Akanda CorpToronto, Ontario--(Newsfile Corp. - November 14, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") is researching the security requirements and next steps for a full cultivation license through its cannabis operating subsidiary. Recently, the Company extended its option on its British Columbia asset for an additional two years. While the Company ...

Successful loading of CBD material accelerates the path to revenue. ORLANDO, FL / ACCESS Newswire / November 4, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced a significant technical milestone: the successful loading of milk-derived exosomes with Cannabidiol (CBD) material. ...

Industry Overview - 2025 is anticipated to be a breakthrough year for the cannabis industry, driven by support from the Trump administration and increasing investor optimism [1][3] - Federal legalization of marijuana could potentially revive the industry, which is projected to exceed $160 billion by 2032 [3] Company Analysis: Village Farms International (VFF) - Village Farms holds a Zacks Rank 1 and has strengthened its position in the cannabis market through strategic restructuring and international expansion [5] - The company divested its fresh-produce business, focusing on higher-margin cannabis operations, leading to a 690% year-over-year increase in international medical export sales [6][7] - Village Farms has maintained its status as one of Canada's top three cannabis companies, consistently generating positive EBITDA and cash flow [7] - EPS estimates for 2025 improved from a loss of 9 cents to earnings of 12 cents, with a stock price increase of 267% year to date [8] Company Analysis: Canopy Growth (CGC) - Canopy Growth, with a Zacks Rank 2, is improving its balance sheet through disciplined capital allocation and cost management [9] - The company is reducing operating costs by stepping back from low-margin businesses and divesting non-core assets, enhancing liquidity for growth opportunities [9] - Canopy Growth's U.S. ambitions are significant, with interests in Acreage Holdings, Wana Brands, and Jetty Extracts, which could benefit from federal rescheduling [11] - Loss per share estimates for 2025 narrowed from 60 cents to 50 cents, despite a 50% stock decline year to date [12] Company Analysis: Tilray Brands (TLRY) - Tilray, ranked 3 by Zacks, is expanding its international operations in Germany and Italy while diversifying beyond cannabis into beer and spirits [13][14] - The company has acquired over a dozen beer and spirits brands, becoming one of the largest craft brewers in the U.S., and has entered the hemp-based THC beverage market [14] - Estimates for Tilray's fiscal 2026 and 2027 remain unchanged at 11 cents and 7 cents, respectively, with shares rising 21% in the past 60 days [15]

Core Viewpoint - Aurora Cannabis (ACB) shares surged over 28% following President Trump's endorsement of cannabidiol (CBD) as a viable alternative to prescription drugs, highlighting its potential to transform senior healthcare and reduce costs [1]. Group 1: Stock Performance - Following the endorsement, ACB stock is up approximately 68% from its year-to-date low [2]. - Options data indicates a potential price range for ACB shares between $3.94 and $7.52, with near-term expectations suggesting a 16.9% move between $4.76 and $6.70 [5]. Group 2: Regulatory Environment - The stock price rally reflects optimism regarding a potential federal policy shift, particularly the rescheduling of marijuana from Schedule I to Schedule III, which could alleviate financial challenges for cannabis firms [3]. - Aurora Cannabis derives about two-thirds of its revenue from medical channels, positioning it well to benefit from favorable regulatory changes in the medical cannabis sector [4]. Group 3: Market Opportunities - The U.S. medical cannabis market is projected to exceed $15 billion in revenue this year, presenting significant growth opportunities for Aurora Cannabis [4]. Group 4: Financial Challenges - Despite the positive market sentiment, Aurora Cannabis faces ongoing financial difficulties, including persistent cash burn that hampers its path to profitability [6]. - The recent surge in ACB shares has led to concerns that they may no longer be undervalued, suggesting a cautious approach for investors [7].

Key Points Tilray's shares initially fell more than 12% shortly after the market opened on Tuesday. Monday's surge followed a video posted by President Trump promoting CBD for seniors, which sparked a sector-wide rally. Even after today's drop, the stock remains up sharply for the week. 10 stocks we like better than Tilray Brands › Shares of Tilray Brands (NASDAQ: TLRY) declined as much as 12.4% on Tuesday, but were down about 9% as of 10:30 a.m. ET. The pullback comes a day after a dramatic rall ...

Core Viewpoint - Tilray (TLRY) shares experienced a significant increase of nearly 60% following President Trump's endorsement of cannabidiol (CBD) as a transformative element in senior healthcare, suggesting potential for substantial medical cost savings of up to $64 billion annually [1][4]. Group 1: Stock Performance - Following the rally, Tilray stock reached a new 52-week high of $1.86 [2]. - Options data indicates heightened volatility for Tilray shares, with traders anticipating a 23.43% price movement by the end of the week, suggesting a trading range of $1.42 to $2.28 [5]. - Longer-dated options expiring on December 19 suggest an even wider range of $0.93 to $2.77, reflecting both optimism and risk [6]. Group 2: Regulatory Impact - The potential rescheduling of marijuana from Schedule I to Schedule III could significantly alter the cannabis industry, allowing access to traditional banking services and more favorable tax treatment [3]. - Trump's support for Medicare coverage of marijuana-related treatments indicates a shift towards federal backing for the CBD industry, which could alleviate criminal penalties and financial restrictions [4]. Group 3: Market Sentiment - The market sentiment appears to be leaning towards the upside, driven by Trump's remarks and speculation regarding federal marijuana rescheduling [5][6]. - Wall Street analysts recommend maintaining a long-term position in Tilray shares, indicating confidence in the company's future prospects [7].

Shares of cannabis and CBD-related companies surged on Monday after US President Donald Trump posted on Truth Social that hemp-derived cannabidiol (CBD), especially in senior healthcare,  “could revolutionize” treatment by reducing disease progression and providing an alternative to prescription drugs.He further reiterated his administration is exploring reclassifying marijuana under federal law, a change that could ease criminal penalties and open broader market access.The market reacted strongly: Tilray B ...

Core Viewpoint - Canopy Growth (CGC) shares experienced an 18% increase following President Trump's endorsement of cannabidiol (CBD) as a potential breakthrough in senior healthcare, suggesting possible marijuana reclassification under his administration [1][3]. Market Reaction - Following the recent rally, Canopy Growth stock has risen over 100% compared to its year-to-date low [2]. Potential Impact of Reclassification - Trump's endorsement could lead to a shift in U.S. policy, allowing Canadian cannabis firms to access the U.S. market more freely, reduce tax burdens, and attract institutional capital [3]. - Reclassification would legitimize cannabis as a mainstream wellness product, potentially increasing demand and improving investor sentiment [4]. - Canopy Growth's existing stake in Acreage Holdings positions the company favorably for expansion and long-term revenue growth if regulatory reforms occur [4]. Financial Concerns - Despite positive sentiment, Canopy Growth continues to face significant financial challenges, including steep losses, negative EBITDA, and dwindling cash reserves [5]. - The company's core Canadian business is declining due to oversupply and price compression, and its U.S. exposure remains limited and dependent on uncertain federal reforms [6]. Wall Street Sentiment - Wall Street maintains a generally positive outlook on Canopy Growth, with a consensus rating of "Hold" and a mean target price of $2.38, indicating a potential upside of 50% [7].

Industry Overview - The cannabis industry is experiencing a positive shift following President Trump's endorsement of cannabidiol (CBD) for senior healthcare, leading to a rally in cannabis shares [1][2] - The U.S.-listed shares of Canadian cannabis companies are seeing significant gains, indicating a strong market reaction [1] Political Influence - Trump's statement on CBD as a potential alternative to traditional prescription drugs may provide momentum for the cannabis industry, which has faced strict regulations [2][3] - The possibility of reclassifying marijuana under federal law could alleviate operational and tax challenges for cannabis businesses, although it would not equate to full legalization [2][3] Market Performance - Analysts highlight that political backing, even if symbolic, is crucial for an industry struggling with regulatory hurdles [3] - The global cannabis market is projected to reach a value of $444.34 billion by 2030, showcasing its high growth potential despite volatility [4] Stock Performance - Notable stock performance includes: - Tilray Brands (TLRY) up 41.3% - Aurora Cannabis (ACB) up 23.6% - Canopy Growth (CGC) up 15.7% - Green Thumb Industries (GTBIF) up 15.7% - Curaleaf Holdings (CURLF) up 20% - Trulieve Cannabis (TCNNF) up 12.7% [5]

Market Trend - Cannabis stocks experienced a rally following President Trump's video promoting CBD coverage under Medicare [1]